Gilead's Letairis Gets Boost Against Actelion's Tracleer With Removal Of Liver Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
REMS helps drive the endothelin receptor antagonist to a cleaner label, as the pulmonary arterial hypertension drug's black box will be modified and liver testing requirements dropped.